# US 2015/0104531 A1 · Trans-aconitic acid compounds and uses thereof for inhibiting phosphodiesterase 7

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104531 A1
- Document ID: US20150104531A1
- Status: Published application
- Kind: A1
- Application number: 14/513,029
- Filed: 2014-10-13
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Academia Sinica
- Applicants: Academia Sinica
- Inventors: Shui-Tein CHEN; I-Shu LEE; Yu-Chun CHEN
- Web page: https://patentgrep.com/patent/US20150104531A1

## CPC

- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K 36/8998: Hordeum (barley)
- A61K 36/9062: Alpinia, e.g. red ginger or galangal
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of inhibiting a phosphodiesterase (PDE) 7 enzyme such as PDE7A1 and methods for treating diseases associated with PDE7 using one or more trans-aconitic acid compounds, which can be isolated from plants.

## Claims

### Claim 1

A method for inhibiting a phosphodiesterase 7 (PDE7), comprising: contacting a PDE7 with a composition comprising a trans-aconitic acid compound in an amount effective in inhibiting the activity of a PDE7.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PDE7 is a human enzyme.

### Claim 3 (depends on 1)

The method of claim 1, wherein the PDE7 is PDE7A1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is a plant extract.

### Claim 5 (depends on 4)

The method of claim 4, wherein the plant extract is prepared from a monocotyledon plant.

### Claim 6 (depends on 5)

The method of claim 5, wherein the monocotyledon plant is shell flower, rice, wheat grass, maize, barley, or sorghum.

### Claim 7 (depends on 4)

The method of claim 4, wherein the plant extract is prepared from leaves or straws of the plant.

### Claim 8 (depends on 7)

The method of claim 7, wherein the plant extract is prepared from leaves or straws of rice, leaves of shell flower, or wheat grasses.

### Claim 9 (depends on 4)

The method of claim 4, wherein the composition comprises the trans-aconitic compound that is purified from a plant.

### Claim 10 (depends on 9)

The method of claim 9, wherein the plant is a monocotyledon plant.

### Claim 11 (depends on 10)

The method of claim 10, wherein the monocotyledon plant is shell flower, rice, wheat grass, maize, barley, or sorghum.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition comprises the trans-aconitic acid compound that is chemically synthesized.

### Claim 13 (depends on 1)

The method of claim 1, wherein the contacting step is performed by administering the composition to a subject having or being at risk for a disease associated with dysregulation of the PDE7 in need thereof, wherein the composition is a pharmaceutical composition which further comprises a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The method of claim 13, wherein the disease is selected from the group consisting of an inflammatory disease, an autoimmune disease, a cardiovascular disease, a neurodegenerative disease, and cancer.

### Claim 15 (depends on 14)

The method of claim 14, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, eczema, atopic dermatitis, and allergic rhinitis.